BNET Industries

Market Cap:$164.3M
Last Fiscal Year Sales:$7.4M
  • Public
  • US
Dow Jones Description

AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. We are developing a broad portfolio of vaccines and immunotherapeutics addressing a wide range of applications including bacterial and viral diseases, and food safety. These include single dose, oral vaccines that protect against important disease causing agents, addressing the traveler's market, pandemic diseases, and global health needs. Our strategy is to demonstrate proof of concept for our products before leveraging their value through partnerships. Our current collaborations encompass the development of an oral human rotavirus vaccine which has received marketing approval in Mexico in over 90 countries worldwide, and vaccines addressed to human food safety and animal health. Our products address large market opportunities for which current therapies are inadequate or nonexistent.

President & CEO
Anthony S. Marucci
Number of Employees 78
Contact Information

119 4th Ave

Needham, Massachusetts 02494-2725

www.avantimmune...

(781) 433-0771

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results

    11/04/09 - Merger / Acquisition - View Story

  • Affitech AS Appoints Dr. Robert Burns as CEO 9/1/2009

    9/02/09 - Merger / Acquisition - View Story

  • Celldex Reports Second Quarter and Six Month 2009 Financial Results

    8/05/09 - Merger / Acquisition - View Story

  • Celldex Therapeutics acquires CuraGen and its oncology antibodies for $94.5 million

    7/01/09 - Merger / Acquisition - View Story

  • CuraGen Is Being Sold: BIOTECH

    5/30/09 - Financial Announcement - View Story

  • Celldex acquires CuraGen for $94.5M

    5/29/09 - Board Member - Entering - View Story

Decision Makers

Name (plus bio) Position
Anthony S. Marucci President & CEO
Avery W. Catlin Senior Vice President and Chief Financial Officer
M. Timothy Cooke COO & Senior Vice President
Thomas Davis Senior Vice President & Chief Medical Officer
Tibor Keler Senior Vice President & Chief Scientific Officer
Timothy Cooke Senior Vice President, Chief Operating Officer
Una S. Ryan CEO
Ronald W. Ellis Senior Vice President, Research and Development
Henry C. Marsh Vice President, Research
Taha Keilani Vice President of Medical and Regulatory Affairs

Board of Directors

Name (plus bio) Position
Charles R. Schaller Chair of Board
Alf A. Lindberg Board of Directors
Francis R. Cano Board of Directors
George O. Elston Board of Directors
Harry H. Penner Jr. Board of Directors
Herbert J. Conrad Board of Directors
Karen S. Lipton Board of Directors
Lane White Pine Board of Directors
Larry Ellberger Board of Directors
Peter A. Sears Board of Directors
Rajesh B. Parekh Board of Directors

Mr. Marucci was a founder of Celldex and Vice President, Chief Financial Officer, Treasurer and Secretary since May 2003 prior to his appointments to Executive Vice President in March 2008, President and Chief Executive Officer in October 2008, and the Board of Directors in December 2008. He was responsible for the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK), as well as the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008. In addition, he was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also serves as its Treasurer. Mr. Marucci received his M.B.A. from Columbia University.

Organization Position Status
CELLDEX THERAPEUTICS, INC. President & CEO Current

Organization Position Status
Celldex Therapeutics, Inc. Senior Vice President & Chief Financial Officer Current
CELLDEX THERAPEUTICS, INC. Senior Vice President and Chief Financial Officer Current
CELLDEX THERAPEUTICS, INC. Board of Directors Current
Endogen, Inc. Chief Financial Officer Former
Repligen Corporation Chief Financial Officer Former
Endogen, Inc. Vice President, Operations and Finance Former
Babson College M.B.A. Former
University of Virginia B.A. Degree Former

Organization Position Status
CELLDEX THERAPEUTICS, INC. COO & Senior Vice President Current

Dr. Davis joined Celldex in 2006 as Vice President of Clinical Development and Chief Medical Officer and was appointed to Senior Vice President in March 2008. He was formerly Chief Medical Officer at GenVec and Senior Director of Clinical Science at Medarex. He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies and vaccines at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr. Ron Levy on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his M.D. from Georgetown University and Oncology training at Stanford University.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Senior Vice President & Chief Medical Officer Current

Dr. Keler was a founder of Celldex and served as Vice President of Research and Discovery since May 2003 prior to his appointment to Senior Vice President and Chief Scientific Officer in March 2008. Previously, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the preclinical development of a number of Medarex clinical product candidates. In addition, Dr. Keler was responsible for the development of Celldex's core technology and related products. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Senior Vice President & Chief Scientific Officer Current

Organization Position Status
CELLDEX THERAPEUTICS, INC. Senior Vice President, Chief Operating Officer Current
Columbia University Ph.D. In Bio, Organic Chemistry Former
Columbia Business School MBA Former

Organization Position Status
Avant LLC Chief Executive Officer Current
Celldex Therapeutics, Inc. President and Chief Executive Officer Current
Iquum, Inc. President and CEO of Avant Immunotherapeutics Current
Boston University School of Medicine Research Professor of Medicine Current
Massachusetts Biotechnology Council Board of Directors Current
The Convergence Guide Board of Directors Current
Nehi Board of Directors Current
Celldex Therapeutics, Inc. Board of Directors Current
Avant LLC Director Current
The Convergence Forum Board of Directors Current
Biotechnology Industry Organization Board of Directors Current
Iquum, Inc. Board of Directors Current
Genocea Board of Directors Current
Visitors Board of Directors Current
Albany Molecular Research, Inc. Board of Directors Current
Whitehead Institute for Biomedical Research Member of the Board Current
CELLDEX THERAPEUTICS, INC. CEO Current
CELLDEX THERAPEUTICS, INC. Chief Operating Officer Former
Avant LLC Chief Scientific Officer Former
Avant LLC Vice President of Research Former
Monsanto Company Director of Health Sciences Former
Washington University School of Medicine Research Professor of Surgery, Medicine and Cell Biology Former
Washington University Research Professor of Surgery, Medicine and Cell Biology Former
CELLDEX THERAPEUTICS, INC. Board of Directors Former
Cambridge University Ph.D. In Cellular and Molecular Biology Former

Organization Position Status
CELLDEX THERAPEUTICS, INC. Senior Vice President, Research and Development Current
Merck & Co. Inc. Former

Organization Position Status
CELLDEX THERAPEUTICS, INC. Vice President, Research Current
CELLDEX THERAPEUTICS, INC. Senior Scientist Former
Abbott Laboratories Scientist Former
Research Triangle Institute Former

Organization Position Status
CELLDEX THERAPEUTICS, INC. Vice President of Medical and Regulatory Affairs Current
Celldex Therapeutics, Inc. Vice President of Medical and Regulatory Affairs Current
Emd Serono, Inc. Medical Director of Clinical Development and Regulatory Affairs Former

Mr. Schaller is the Chairman of the Board of Directors of Celldex and became a Director of Celldex in November 2006. Mr. Schaller has been a Director of Medarex, Inc. since its inception in 1987 and served as Chairman of the Medarex Board of Directors from 1987 - 1997. Since 1989, Mr. Schaller has been a chemical industry development consultant and, until June 2002, he served as a director of AstroPower, Inc., a major U.S. manufacturer of photovoltaic (PV) products, now part of General Electric. Mr. Schaller is a chemical engineering graduate of Yale University and is a graduate of the Harvard Business School Program for Management Development.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Chair of Board Current
Celldex Therapeutics, Inc. Chair of Board Current
Avant LLC Chairman of the Board of Directors Current
Medarex, Inc. Board of Directors Current
Astropower, Inc. Director Former
Yale University Former
Harvard Business School Former

Organization Position Status
Celldex Therapeutics, Inc. Chief Executive Officer of Nobel Web Ab Current
Pharmexa Professor, MD and PhD Current
Pharmexa Board Member of Pharmexa Current
Celldex Therapeutics, Inc. Board of Directors Current
CELLDEX THERAPEUTICS, INC. Board of Directors Current
Proteome Sciences Plc Board of Directors Current

Organization Position Status
Biomerica, Inc. Board of Directors Current
Lancer Orthodontics Inc. Board of Directors Current
CELLDEX THERAPEUTICS, INC. Board of Directors Current
Arbor Vita Corporation Board of Directors Current
Celldex Therapeutics, Inc. Board of Directors Current
Vaxin, Inc Chief Executive Officer Former
Aviron President Former
Aviron Chief Operating Officer Former
Aviron Co-Founder Former
Vaxin, Inc Chairman Former
The Pennsylvania State University Ph.D. Degree In Microbiology Former

Mr. Elston became a Director of Celldex in March 2004 and is the Chief Financial Officer of Optherion, Inc., a privately held biopharmaceutical company located in New Haven, Connecticut. Mr. Elston has more than 20 years of financial and business expertise in the biotechnology and medical device industries. Before joining Optherion, Mr. Elston was with Elusys Therapeutics where he raised significant funding from government and private sources, completed multiple strategic collaborations with large pharmaceutical and biotechnology firms, and oversaw collaborations with the U.S. Department of Defense and the National Institutes of Health. Before joining Elusys, Mr. Elston was Chief Financial Officer of Trillium USA, Inc., where he established the financial and administrative functions for the Company’s multi-national operations. Previously, Mr. Elston was with C.R. Bard, Inc., an international manufacturer and distributor of medical devices, where he directed financial operations for multiple manufacturing facilities and successfully integrated strategic acquisitions; and with Price Waterhouse. Mr. Elston received his B.B.A. in Public Accounting from Pace University and is a Certified Public Accountant.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Board of Directors Current

Organization Position Status
Makscientific, LLC President, CEO and Vice Chairman Current
Rib-X Pharmaceuticals Co-Founder Current
Rxgen, Inc Chairman and Co-Founder Former
Rxgen, Inc Board of Directors Current
RHEI Pharmaceuticals, Inc. Board of Directors Current
Altus Pharmaceuticals Inc. Board of Directors Current
BioStratum Incorporated Board of Directors Current
Celldex Therapeutics, Inc. Board of Directors Current
Rib-X Pharmaceuticals Board of Directors Current
Ikonisys, Inc. Board of Directors Current
CELLDEX THERAPEUTICS, INC. Board of Directors Current
Neurogen Corporation Chief Executive Officer Former
Ikonisys, Inc. Chairman, CEO of Nascent Bioscience, Llc Former
Marinus Pharmaceuticals Inc. Chief Executive Officer Former
Neurogen Corporation President Former
Novo Nordisk, Inc. Executive Vice President Former
Makscientific, LLC Co-Founder Former
Boehringer Ingelheim Corporation Corporate Counsel Former
Connecticut, Inc. Bioscience Advisor Former
Celldex Therapeutics, Inc. Chairman Former
Marinus Pharmaceuticals Inc. Chairman Former
Marinus Pharmaceuticals Inc. Director Current
The Cure, Inc. Co-Chair Former
PRA International Inc. Board Member Former
Neurogen Corporation Vice Chairman Former
Connecticut-Business.Com Director Former
Packard Bioscience Company Board Member Current
New York University Ll.M. In International Law Former
University of Virginia B.A. Former
University of Virginia Degrees Former
New York University Degrees Former
Fordham University Degrees Former

Mr. Conrad became a Director of Celldex in March 2004. Mr. Conrad was the former president of Roche Pharmaceuticals in the United States from 1982 until his retirement in 1993. Since then he has served on the boards of Dura, UroCor, Sicor, GenVec (chairman), Bone Care International (chairman) and was a co-founder of Reliant Pharmaceuticals. Mr. Conrad is currently chairman of Sapphire Therapeutics and is on the boards of Savient Pharmaceuticals, Pharmasset Inc., and Symphony Evolution. He received B.S. and M.S. degrees from Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Board of Directors Current

Ms. Lipton became a Director of Celldex in May 2001. She was appointed Chief Executive Officer of AABB in October 1994. Prior to AABB, she held senior positions for 10 years at the American Red Cross including Acting Senior Vice President, Biomedical Services (1993-1994) and General Counsel and Secretary (1990-1993). Prior to the American Red Cross, Ms. Lipton was a lawyer in private practice. She received her BA from Yale University and J.D. from Case Western Reserve University School of Law.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Board of Directors Current

Organization Position Status
CELLDEX THERAPEUTICS, INC. Board of Directors Current

Mr. Ellberger became a Director of Celldex in August 2003. In October 2005, Mr. Ellberger was appointed interim Chief Executive Officer of PDI, Inc., where he had been serving as a Director and Chairman of the Audit Committee. Mr. Ellberger was a Board member and Senior VP of Powderject PLC from 1999-2003. Prior to joining Powderject, Mr. Ellberger was an officer of W.R. Grace & Co. from 1995 to 1999, serving as Interim Chief Executive Officer in 1997-1998, Chief Financial Officer from 1996 and Senior Vice President, Strategic Planning and Development from 1995. From 1975 to 1995, Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. In addition to his position at HVA, a healthcare transaction advisory firm, Mr. Ellberger is currently Chairman of the Board of Omrix Biopharmaceuticals, Inc. and is a Director of TransPharma Medical Ltd. and the Jewish Children’s Museum.

Organization Position Status
Omrix Biopharmaceuticals, Inc Chairman Current
PDI, Inc. Board of Directors Current
CELLDEX THERAPEUTICS, INC. Board of Directors Current
PDI, Inc. Interim CEO & Chief Admin Officer Former
W.R. Grace & Company CEO Former
PDI Inc. Interim Chief Executive Officer Former
CELLDEX THERAPEUTICS, INC. Interim Chief Executive Officer, Pdi, Inc. Former
W.R. Grace & Company Chief Financial Officer Former
PDI Inc. Chief Administrative Officer Former
PDI, Inc. Chief Administrative Officer Former
Powderject Pharmaceuticals, Plc Senior Vice President, Corporate Development Former
W.R. Grace & Company Senior Vice President, Strategic Planning and Development Former
CELLDEX THERAPEUTICS, INC. Vice President, Corporate Development Former
PDI Inc. Director and Chairman Former
American Cyanamid Company Senior Executive Former
Powderject Pharmaceuticals, Plc Board Member Former
Omrix Biopharmaceuticals, Inc Board of Directors Former
PDI, Inc. Director Former

Organization Position Status
Bioadvance Ventures, Inc Venture Director Current
Immune Control Inc Current
Quaker Bioventures Current
Japan America Society of Greater Philadelphia Co-Chair Current
CELLDEX THERAPEUTICS, INC. Board of Directors Current
Vybion, Inc. Director Current
University City Science Center Director Current
Viral Therapeutics Director Current
Fox Chase Bank Inc. Board of Directors Current
Dxrxproteins Latest Member of The Board of Directors Current
S.R. One Limited President Former
Protez Pharmaceuticals Inc Vice President, Corporate Development Former
Fox Chase Bank Inc. Vice President Former
Japan America Society of Greater Philadelphia Director Emeritus Former
Protez Pharmaceuticals Inc Attorney Former
Fox Chase Bank Inc. Assistant Secretary Former
GlaxoSmithKline Plc Former
University City Science Center Chairman Former
Protez Pharmaceuticals Inc Board of Directors Former
Harvard Law School Jd Degree Former
Colgate University Former

Dr. Parekh became a Director of Celldex in March 2004. He is a General Partner at Advent Venture Partners (UK) whom he joined in 2005. He was a co-founder and served as Chief Scientific Officer and Senior Vice President of Research and Development of Oxford GlycoSciences, plc (UK) from 1988 to 2003. Dr. Parekh is Chairman of Galapagos nv (Belgium) and currently serves on the Board of Directors of seven companies in the United States and Europe. He received his B.A. and D.Phil. degrees in Biochemistry and Molecular Medicine from the University of Oxford where he has also been a Visiting Professor.

Organization Position Status
CELLDEX THERAPEUTICS, INC. Board of Directors Current

Executive News

  • Celldex Therapeutics Announces Appointment of Larry Ellberger as Chairman of the Board

    TradingMarkets - 9/04/09 - View Story

  • Celldex Therapeutics Announces Appointment of Larry Ellberger as Chairman of the Board

    Business Wire - 9/04/09 - View Story

advertisement
     CLDX $5.20 +0.01 (0.19% )
Average Volume 333,237
Shares Outstanding 15.88M
Market Cap 82.6M
Year High 14.19
Year Low 4.16
Earnings Per Share -1.95
P/E Ratio -2.67
Dividend N/A
Yield N/A
advertisement